CD274 and non-small cell lung carcinoma: To date, six kinds of monoclonal antibodies of PD-1/PD-L1 have been approved by FDA, for the treatment of non-small cell lung cancer (NSCLC), melanoma, Hodgkin’s lymphoma and gastric cancer and more.